Beckman Coulter Completes Acquisition of Olympus' Lab-Based Diagnostics Business

ORANGE COUNTY, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc.
(NYSE: BEC), a leading developer, manufacturer and marketer of products that
simplify, automate and innovate complex biomedical testing, announced today
the completion of the acquisition of Olympus' lab-based diagnostics business.
This acquisition, first announced in February, extends Beckman Coulter's
leadership position in Chemistry and Automation.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO )

Scott Garrett, chairman, president and chief executive officer, said, "The
completion of this transaction adds considerable product depth and
significantly expands our geographic reach and scale. We are confident that
the combination of Olympus diagnostics with our business will provide many
cross-selling opportunities -- the most compelling being promotion of Beckman
Coulter's leading Immunoassay products to the loyal base of Olympus' chemistry
customers.

"We remain focused on creating shareholder value through growth, quality and
operating excellence. This acquisition demonstrates Beckman Coulter's
commitment to further extend our leadership position in chemistry and sustain
our above-market growth in immunoassay," concluded Garrett.

Beckman Coulter delivered approximately 76 billion Japanese yen in cash, or
approximately USD $780 million, which was funded as follows:

-- Approximately $495 million in net proceeds raised from the issuance of
two $250 million senior note offerings of 6- and 10- year maturities
with 6% and 7% coupons, respectively.

-- Approximately $240 million in a common stock offering comprised of
approximately 4.7 million shares issued to the public at $53.00 per
share, or $50.75 net proceeds per share. In connection with the
offering, Beckman Coulter entered into forward sale agreements which
were settled July 27, 2009, at which time the newly issued shares were
added to Beckman Coulter's total outstanding shares.

The company expects to provide additional details on the impact of the
transaction on 2009 results during the company's third quarter earnings news
release and conference call in late October, and expectations for 2010 will be
included at the company's Annual Business Review on December 17, 2009.

About Beckman Coulter

Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures
and markets products that simplify, automate and innovate complex biomedical
tests. More than 200,000 Beckman Coulter systems operate in laboratories
around the world, supplying critical information for improving patient health
and reducing the cost of care. Recurring revenue, consisting of consumable
supplies (including reagent test kits), service and operating-type lease
payments, represent about 78% of the company's 2008 revenue of $3.1 billion.
For more information, visit www.beckmancoulter.com.

Contact: Cynthia Skoglund
(714) 773-7620
Manager, Investor Relations

SOURCE Beckman Coulter, Inc.

Cynthia Skoglund, Manager, Investor Relations of Beckman Coulter, Inc.,
+1-714-773-7620